High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities

Whijae Roh; Yifat Geffen; Hongui Cha; Mendy Miller; Shankara Anand; Jaegil Kim; David I. Heiman; Justin F. Gainor; Peter W. Laird; Andrew D. Cherniack; Chan‐Young Ock; Se‐Hoon Lee; Gad Getz

doi:10.1158/0008-5472.can-22-0432

August 30, 2022Cancer ResearchOpen Access

High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Integrative analysis of multiomic and drug dependency data uncovers robust lung adenocarcinoma expression subtypes with unique therapeutic vulnerabilities and subtype-specific biomarkers of response.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roh et al. (2022) studied this question.

synapsesocial.com/papers/69de8bf6bf539e22705590b7 https://doi.org/10.1158/0008-5472.can-22-0432

View Full Paper

Ask AI

Bookmark

Share

High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities

Abstract

Ask about this paper

Discussion

Cite This Study

High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading